绥美凯属于医保报销药品吗？

On January 20, 2018, ViiV, a joint venture company under GlaxoSmithKline (hereinafter referred to as GSK), launched the first complete antiviral treatment program drug with dolutegravir (also known as DTG in English) as the core - (dolutegravir tablets) in China. This is also the first complete single-pill compound treatment program in the field of HIV treatment in China. After the drug was launched in China, it can be said to have brought good news to AIDS patients, and its price is also of great concern to patients. So, is Suimeikan a drug reimbursed by medical insurance?

The price of Suimeikai in the domestic market is close to 3,000$/box. Although it is not a sky-high price, long-term treatment will also incur high costs, thereby increasing the financial burden and psychological pressure of patients. However, it is regrettable that Suimeikai is still not included in the national medical insurance directory, which means that patients cannot be reimbursed by medical insurance when purchasing the drug. In order to reduce their financial burden as much as possible, patients have turned their attention to India, known as the "pharmaceutical factory of the world".

Fortunately, the Indian version of Suimeikai has been successfully launched. According to Medical Companion Travel, a box of Suimeike (Domitabalamid Tablets) produced by Emcure in India is priced at around $900 and contains 30 tablets. The Indian version of Suimeike not only has an advantage in price, but patients can also continue to benefit from it by insisting on taking the medication. Patients in need can go abroad to purchase locally in India, or contact Medical Companion Travel to obtain drug purchase channels for Suimeikai.

After purchasing Suimeike (Dolutea Balamib Tablets), patients must follow the instructions for use. For adults and teenagers whose weight must be at least 40kg and above, the recommended dosage of Suimeikai is one tablet once a day. When the patient's weight is less than 40kg, in principle, he cannot take treatment because Suimeikai is a fixed-dose tablet and the dose cannot be reduced or increased without authorization.

Recommended hot articles: /newsDetail/83731.html